The call ran from 9:31 AM to 10:43 AM IST (1 h 12 min).
Key takeaways
Q2 FY27 revenue ₹280 Cr (+43%) and EBITDA ₹94 Cr (+88%) were flattered by a ₹53 Cr one-time DCV milestone. Management sounds confident, but pricing and timing answers stayed unquantified.
| Management target | Revenue 20.0% FY27 |
|---|
| Revenue growth | Q2 +43% YoY, H1 +25%; includes ₹53 Cr one-time milestone revenue. |
|---|---|
| Margins | API gross margin steady above 60%; API EBITDA margin stable near 30%. |
| Order book | Take-or-pay capacity contracted; contract values withheld for confidentiality. |
| Demand visibility | Claims strong traction in biomanufacturing; no quantified demand data disclosed. |
| Management confidence | Over-optimistic; defers specifics on pricing, Premarin, and capacity numbers. |
Growth
Q2 revenue +43% YoY, but ₹53 Cr one-time milestone inflates it. API +16%, volume-led, the organic core.
Outlook
FY27 guidance maintained: ~20% revenue growth, ~25% EBITDA growth, ±5ppt. Annual capex ₹200–300 Cr.
Risks
Milestone-driven revenue is lumpy; receivables jumped to ₹268 Cr; API price pressure; US approval slipping to late CY27.
Last quarter's promises, checked
Delivered
- Guided API growth high-single-digit → Q2 API +16%, H1 +11% (= BEAT)
- Guided H2 milestones to offset ₹23Cr/qtr new-biz opex → ₹53Cr DCV milestone booked in Q2 (= BEAT)
- Guided API gross margin 60%+ → above 60% (= BEAT)
Partly delivered
- Guided FY27 revenue ~20%, EBITDA ~25% (±5ppt) → H1 revenue +25% incl. ₹53Cr one-time (= PARTIAL)
- Guided capex ₹200–250Cr/yr → plan now ₹200–300Cr; H1 spend ₹113Cr (= PARTIAL)
Summary by ALFA Finder, written with AI assistance from our own recording of the call, published . Open it on ALFA Filings ›
What management said last time
Full summary →From the call summary published .
Outlook they gave
Management guides 20% revenue and 25% EBITDA growth for FY27, backed by Q3/Q4 milestone cashflows.
Growth they described
Core API business grew 6% YoY on volumes; new CDMO/Injectables segments contribute ₹34 Cr in combined costs without revenue.
Call details
| Company | Symbiotec Pharmalab Ltd |
|---|---|
| NSE symbol | SYMBIOTEC |
| ISIN | INE899I01028 |
| Call | Q2 FY27 earnings call |
| Date | Friday, 6 November 2026 |
| Time | 9:30 AM IST |
| Length | 1 h 12 min |
| Audio | Our stream on YouTube ↗ |
Symbiotec Pharmalab Ltd: key numbers
- Share price
- ₹1,525.80
- Market cap
- ₹9,804 Cr
- Revenue (annual)
- ₹869.1 Cr
- Net profit (annual)
- ₹109.9 Cr
- Promoter holding
- 33.28%
- FII holding
- 3.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Other calls on Fri, 6 Nov
Today's concalls →
